Last updated: November 2, 2026
HAEGARDA is CSL Behring’s subcutaneous C1 esterase inhibitor for routine prevention of hereditary angioedema, or HAE, attacks. Its commercial position is supported by a differentiated self-administered delivery system, established physician familiarity with C1 inhibitor replacement, and limited biosimilar competition. The main constraints are high treatment cost, plasma supply requirements, competition from longer-acting and oral prophylactic products, and the absence of separately disclosed product revenue.
CSL does not report HAEGARDA sales as a standalone line item. Financial analysis therefore relies on CSL Behring’s broader specialty and plasma-product performance, prescription trends, market share indicators, and the growth of competing HAE therapies.
What is HAEGARDA and how does it work?
HAEGARDA is a plasma-derived human C1 esterase inhibitor administered by subcutaneous injection twice weekly. It is approved in the United States for routine prophylaxis against hereditary angioedema attacks in adolescent and adult patients.
| Product attribute |
HAEGARDA |
| Active ingredient |
C1 esterase inhibitor, human |
| Manufacturer |
CSL Behring |
| FDA application |
BLA 761092 |
| FDA approval |
2017 |
| Administration |
Subcutaneous injection |
| Primary use |
Routine prevention of HAE attacks |
| Patient population |
Adolescents and adults under the original U.S. approval |
| Dosing pattern |
Twice weekly, weight-based |
| Product class |
Plasma-derived biologic |
| Regulatory pathway |
Biologics license application |
| Primary competitors |
Takhzyro, Orladeyo, Cinryze, Ruconest |
HAEGARDA replaces deficient or dysfunctional C1 inhibitor, which reduces excessive activation of the kallikrein-kinin pathway and limits bradykinin-mediated vascular permeability. Its subcutaneous route allows administration outside an infusion center and is a major commercial differentiator compared with older intravenous C1 inhibitor products.
How large is the HAEGARDA market?
The U.S. hereditary angioedema market is a high-value orphan-drug market with a small diagnosed population and substantial annual treatment cost per patient. Market size estimates vary because companies do not disclose consistent patient counts, net pricing, or product-level revenue.
The market has several structural characteristics:
- Most revenue comes from chronic prophylaxis rather than acute rescue treatment.
- Treatment persistence is high because uncontrolled HAE attacks can require emergency care and hospitalization.
- Switching is influenced by administration burden, attack control, tolerability, payer coverage, and patient preference.
- New oral and longer-acting products are expanding the addressable treatment pool while pressuring injectable therapies.
- Plasma-derived products retain supply-chain value because their manufacturing process is difficult to replicate quickly.
HAEGARDA competes in the prophylaxis segment rather than the acute-treatment segment. It therefore competes most directly with Takeda’s Takhzyro and BioCryst’s Orladeyo.
How does HAEGARDA compare with Takhzyro?
| Factor |
HAEGARDA |
Takhzyro |
| Company |
CSL Behring |
Takeda |
| Active ingredient |
C1 esterase inhibitor |
Lanadelumab |
| Product type |
Plasma-derived replacement protein |
Monoclonal antibody |
| Administration |
Subcutaneous, generally twice weekly |
Subcutaneous, generally every two weeks or monthly under applicable dosing |
| Mechanism |
Replaces C1 inhibitor |
Inhibits plasma kallikrein |
| FDA approval |
2017 |
2018 |
| Main commercial advantage |
Established C1 inhibitor platform and self-administration |
Lower injection frequency and strong efficacy profile |
| Main risk |
Twice-weekly dosing and plasma dependence |
High price and biologic patent/exclusivity exposure |
Takhzyro has generally been the stronger commercial growth product in the prophylaxis market because of its longer dosing interval and substantial physician adoption. Takeda reported approximately $1 billion in annual Takhzyro sales in recent fiscal periods, while CSL does not report HAEGARDA revenue separately. [1,2]
HAEGARDA remains relevant for patients who prefer C1 inhibitor replacement, have clinical reasons to avoid kallikrein inhibition, or obtain favorable reimbursement under CSL’s coverage programs.
How does HAEGARDA compare with Orladeyo?
Orladeyo is an oral, once-daily kallikrein inhibitor developed by BioCryst. Its tablet formulation addresses a key limitation of injectable prophylaxis: administration burden.
| Factor |
HAEGARDA |
Orladeyo |
| Route |
Subcutaneous injection |
Oral tablet |
| Dosing |
Twice weekly |
Once daily |
| Active ingredient |
Human C1 esterase inhibitor |
Berotralstat |
| Manufacturing |
Plasma-derived biologic |
Small-molecule drug |
| Competitive strength |
Replacement therapy and long clinical experience |
Convenience and no injection requirement |
| Commercial vulnerability |
Injection frequency |
Daily adherence and gastrointestinal tolerability considerations |
Orladeyo creates competitive pressure even where HAEGARDA provides strong attack prevention. Patients who place a high value on avoiding injections may switch despite the clinical familiarity of C1 inhibitor therapy.
What is HAEGARDA’s financial trajectory?
HAEGARDA revenue is not separately disclosed by CSL. CSL reports consolidated revenue and segment results for CSL Behring, but its public filings generally combine products across immunoglobulins, specialty products, albumin, and other plasma-derived therapies.
| Financial indicator |
Public disclosure status |
| HAEGARDA annual net sales |
Not separately disclosed |
| HAEGARDA gross margin |
Not separately disclosed |
| HAEGARDA patient count |
Not separately disclosed |
| HAEGARDA U.S. market share |
Not consistently disclosed |
| CSL Behring revenue |
Reported at segment level |
| CSL plasma collection economics |
Reported at group or segment level |
| Takhzyro revenue |
Reported by Takeda |
| Orladeyo revenue |
Reported by BioCryst |
The financial trajectory is best characterized as mature growth rather than early launch expansion. HAEGARDA launched into an established market with an existing C1 inhibitor treatment platform, but it gained commercial value from converting intravenous prophylaxis to home-based subcutaneous administration.
Its growth drivers include:
- Increased diagnosis of hereditary angioedema.
- Greater use of routine prophylaxis.
- Patient conversion from intravenous C1 inhibitor therapy.
- Continued demand for non-oral biologic treatment.
- Broader insurer recognition of home-administered specialty therapies.
- Higher treatment intensity among patients with frequent or severe attacks.
Its financial risks include:
- Competition from Takhzyro’s less frequent dosing.
- Conversion to Orladeyo among injection-averse patients.
- Payer pressure on specialty-drug reimbursement.
- Plasma collection costs and supply volatility.
- Potential future competition from additional kallikrein inhibitors and long-acting C1 inhibitor products.
- Product-level revenue cannibalization within CSL’s broader HAE portfolio.
CSL’s broader financial performance has been affected by plasma collection volumes, donor compensation, labor costs, and the recovery of immunoglobulin demand after pandemic-related disruptions. HAEGARDA benefits from CSL’s plasma infrastructure but also bears the economics of plasma-derived manufacturing. [3]
When does HAEGARDA lose regulatory exclusivity?
HAEGARDA received U.S. orphan-drug designation for hereditary angioedema. The standard orphan-drug exclusivity period is seven years from approval, during which FDA generally cannot approve the same drug for the same indication unless statutory exceptions apply.
| Exclusivity type |
Approximate date |
| U.S. approval |
2017 |
| Seven-year orphan exclusivity |
Approximately 2024 |
| Twelve-year reference-product biologic exclusivity |
Approximately 2029 |
| Earliest practical biosimilar approval |
Generally no earlier than 2029, subject to statutory and regulatory conditions |
The seven-year orphan period and the 12-year reference-product exclusivity period are different protections. Expiration of orphan exclusivity does not create an automatic generic or biosimilar launch opportunity.
Under the Biologics Price Competition and Innovation Act, a biosimilar applicant generally cannot submit a 351(k) application until four years after the reference product’s first licensure, and FDA generally cannot approve the application until 12 years after first licensure. HAEGARDA’s 2017 approval therefore places the principal statutory biologic exclusivity boundary around 2029. [4,5]
The practical launch date could be later because of patent disputes, settlement agreements, manufacturing readiness, interchangeability issues, or FDA review timing.
What patents protect HAEGARDA?
HAEGARDA is a biologic, so its U.S. patent position is not presented through the FDA Orange Book in the same manner as a conventional small-molecule drug. Patent information for biologics is handled through the Purple Book framework and related patent-exchange procedures under the BPCIA.
The principal protection categories are:
| Protection category |
Relevance to HAEGARDA |
| Composition patents |
May cover C1 esterase inhibitor preparations or defined structural characteristics |
| Formulation patents |
May cover stabilized protein formulations, excipients, concentration, or storage conditions |
| Delivery patents |
May cover subcutaneous administration or device configurations |
| Manufacturing patents |
May cover plasma fractionation, purification, viral inactivation, or product consistency |
| Method-of-use patents |
May cover prophylaxis against HAE attacks or patient-specific treatment regimens |
| Regulatory exclusivity |
Includes orphan exclusivity and biologic reference-product exclusivity |
A precise patent-expiration analysis requires claim-level review of patents assigned to CSL Behring, CSL Limited, or related entities and confirmation of terminal disclaimers, patent-term adjustments, patent-term extensions, continuations, and divisional applications.
The absence of an Orange Book listing should not be interpreted as an absence of patent protection. For HAEGARDA, manufacturing and formulation patents may be commercially important even when they do not appear in an Orange Book-style product listing.
What formulation patents and manufacturing barriers affect HAEGARDA?
The most defensible barriers to rapid competition are likely to be manufacturing complexity and regulatory comparability rather than a single formulation patent.
HAEGARDA is a plasma-derived protein product. A biosimilar developer must demonstrate consistency across:
- Source plasma collection.
- Donor screening and viral testing.
- Fractionation and purification.
- Viral inactivation and removal.
- Protein concentration and stabilization.
- Subcutaneous delivery performance.
- Immunogenicity and clinical comparability.
- Batch-to-batch quality controls.
Plasma supply is a structural barrier. A competing manufacturer needs access to sufficient qualified plasma, collection centers, validated fractionation capacity, and a regulatory history supporting consistent product quality.
This barrier is stronger for HAEGARDA than for a conventional oral drug. It does not eliminate biosimilar risk, but it can slow entry, raise development costs, and favor incumbent manufacturers with established plasma networks.
Are there Paragraph IV challenges to HAEGARDA?
Paragraph IV litigation does not apply to HAEGARDA in the same way it applies to an FDA-approved small-molecule drug listed in the Orange Book.
HAEGARDA is approved under a biologics license application. A competing biologic would generally use the 351(k) biosimilar pathway rather than an abbreviated new drug application with a Paragraph IV certification.
| Legal issue |
HAEGARDA status |
| Orange Book patent listing |
Not the primary framework |
| Paragraph IV certification |
Not applicable in the conventional small-molecule sense |
| Biosimilar pathway |
351(k) |
| Reference-product exclusivity |
Approximately through 2029 |
| Patent dispute mechanism |
BPCIA patent-exchange and litigation process |
| Generic substitution |
Not applicable as automatic pharmacy substitution |
No publicly disclosed HAEGARDA-specific Paragraph IV settlement is established by the FDA approval record. Any future biosimilar dispute would likely involve BPCIA patent litigation, manufacturing patents, formulation patents, or process patents.
What is the FDA and Orange Book status of HAEGARDA?
HAEGARDA is FDA-approved and marketed in the United States under BLA 761092. It is not evaluated through the standard abbreviated new drug application pathway.
The Orange Book is primarily used for approved small-molecule drugs and their listed patents and exclusivity. Biologic competitors must be assessed through the Purple Book, FDA biologic approvals, BPCIA exclusivity rules, and company patent disclosures. [4]
HAEGARDA’s approval supports continued commercialization, but it does not guarantee protection from future biosimilar approval after the applicable reference-product exclusivity period.
Which companies are challenging HAEGARDA commercially?
The main competitive threats are established branded therapies rather than generic manufacturers.
Takhzyro
Takeda’s Takhzyro is the leading direct commercial challenger in chronic HAE prophylaxis. Its dosing interval is a major advantage and has supported substantial sales growth.
Orladeyo
BioCryst’s Orladeyo is the main oral prophylaxis challenger. Its commercial proposition is based on avoiding injections and expanding treatment uptake among patients who prefer oral therapy.
Cinryze
Cinryze is an intravenous C1 esterase inhibitor used for prophylaxis. HAEGARDA’s subcutaneous route provides a convenience advantage over Cinryze, although both products rely on C1 inhibitor replacement.
Ruconest
Ruconest is a recombinant C1 esterase inhibitor primarily associated with acute treatment rather than direct chronic-prophylaxis competition. Its recombinant manufacturing platform differentiates it from plasma-derived HAEGARDA.
What generic or biosimilar launch risks exist for HAEGARDA?
The near-term risk of a conventional generic launch is low because HAEGARDA is a biologic. The medium-term risk is a biosimilar or follow-on biologic after the applicable reference-product exclusivity period.
Near-term risk: low
No conventional generic can substitute for HAEGARDA through an ANDA pathway. The product’s orphan exclusivity has likely expired, but biologic reference-product exclusivity and technical development barriers remain relevant.
Medium-term risk: moderate
After the statutory exclusivity period, a biosimilar applicant could pursue a 351(k) application. Risk would depend on whether a competitor can establish analytical similarity, clinical comparability, manufacturing capacity, and an acceptable patent position.
Long-term risk: rising
Once a first biosimilar establishes regulatory and payer acceptance, additional entrants could pressure price and market share. HAEGARDA’s defensibility would then depend on switching friction, physician preference, patient stability, payer contracts, and manufacturing cost.
How strong is the HAEGARDA patent estate?
HAEGARDA has a moderately strong commercial protection profile, but its durability is based on multiple layers rather than a clearly disclosed blockbuster patent cliff.
| Factor |
Assessment |
| Orphan exclusivity |
Expired or expiring around 2024 |
| Reference-product exclusivity |
Strong statutory protection through approximately 2029 |
| Manufacturing barriers |
High |
| Plasma supply barrier |
High |
| Formulation and process protection |
Potentially meaningful, requiring claim-level validation |
| Conventional generic risk |
Low |
| Biosimilar risk before 2029 |
Limited by statutory exclusivity |
| Biosimilar risk after 2029 |
Moderate and increasing |
| Competitive product risk |
High relative to generic risk |
| Pricing pressure |
Moderate to high from payer management and oral alternatives |
The central commercial weakness is not an immediate patent cliff. It is competitive substitution by products with less frequent dosing or oral administration.
What licensing deals affect HAEGARDA?
HAEGARDA is an internally commercialized CSL Behring product. Its principal value chain is controlled by CSL through plasma collection, manufacturing, regulatory ownership, and commercialization.
No major external licensing transaction is required to explain HAEGARDA’s current market position. The relevant strategic asset is CSL’s integrated plasma business, which gives the product access to supply, quality systems, and specialty-commercial infrastructure.
Licensing risk is more relevant to future entrants. A biosimilar or follow-on C1 inhibitor developer may need partnerships for plasma supply, manufacturing, regional commercialization, or specialty distribution.
Key Takeaways
- HAEGARDA is a subcutaneous, plasma-derived C1 esterase inhibitor for routine HAE prophylaxis.
- CSL does not disclose HAEGARDA revenue separately, so product-level financial performance cannot be calculated from public company filings.
- Takhzyro is the strongest direct commercial competitor because of its longer dosing interval.
- Orladeyo is the strongest convenience-based challenger because it is taken orally.
- HAEGARDA’s seven-year orphan exclusivity likely ended around 2024, but biologic reference-product exclusivity generally extends to approximately 2029.
- Paragraph IV litigation is not the relevant framework. Future challenges would proceed through the 351(k) biosimilar pathway and BPCIA patent procedures.
- Plasma supply, fractionation capacity, manufacturing controls, and comparability requirements create meaningful barriers to entry.
- The principal risk is competitive erosion from longer-acting and oral prophylaxis, not an immediate conventional generic launch.
- HAEGARDA’s financial outlook is stable but increasingly dependent on patient retention, reimbursement, plasma economics, and CSL’s ability to defend C1 inhibitor therapy against newer mechanisms.
Frequently Asked Questions
Can HAEGARDA be substituted automatically at the pharmacy?
No. HAEGARDA is a biologic, and automatic substitution depends on FDA interchangeability status, state law, payer policy, and product-specific pharmacy rules.
Is HAEGARDA the same as Berinert?
No. Both are human C1 esterase inhibitor products, but they have different FDA-approved uses, formulations, administration instructions, and commercial positioning.
Is HAEGARDA a plasma-derived or recombinant product?
HAEGARDA is plasma-derived. This distinguishes it from recombinant C1 inhibitor products such as Ruconest.
Does HAEGARDA treat acute HAE attacks?
HAEGARDA is indicated for routine prophylaxis. It is not the principal product used for rapid treatment of an acute HAE attack.
What is the biggest long-term threat to HAEGARDA sales?
The largest long-term threat is substitution by less frequently administered biologics and oral prophylactic therapies, particularly Takhzyro and Orladeyo.
References
- Takeda Pharmaceutical Company Limited. (2024). Annual report 2024.
- BioCryst Pharmaceuticals, Inc. (2024). Annual report 2023.
- CSL Limited. (2024). Annual report 2024.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2024). Reference product exclusivity and biosimilar biological products under the Biologics Price Competition and Innovation Act.
- U.S. Food and Drug Administration. (2017). HAEGARDA prescribing information, BLA 761092.